AstraZeneca licenses EGFR lung cancer drug Zegfrovy from spinoff Dizal for up to $1.5B on July 14, 2026 Approved AstraZeneca China Dizal Pharmaceutical Epidermal Growth Factor Receptor License Malignant neoplasm of lung Non-Small Cell Lung Carcinoma United States Food and Drug Administration Zegfrovy +
Glenmark Pharma Signs $1.1 Billion Deal with Hengrui for HER2-Targeted Antibody-Drug Conjugate on September 25, 2025 Cancer Therapeutic Procedure Glenmark Hengrui Pharma HER2-targeting antibody drug conjugate License milestone payments Neoplasms royalties Trastuzumab Rezetecan +
Fosun Licenses Immunology Asset FXS6837 to Sitala in $670M Deal on August 28, 2025 Autoimmune Diseases Fosun Pharma FXS6837 Immunology License Sitala +
Novartis Bets on Covalent Chemistry in $1B Matchpoint Therapeutics Deal on July 25, 2025 Advanced phase biotechnology partnerships covalent chemistry Covalent Interaction Drug Development Inflammatory disorder License Matchpoint Therapeutics Novartis oral inhibitors +